GLP 4586
Alternative Names: GLP-4586Latest Information Update: 11 Aug 2022
At a glance
- Originator Galapagos NV
- Developer Fibrocor Therapeutics; Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Fibrosis
Most Recent Events
- 04 Aug 2022 Discontinued - Preclinical for Fibrosis in Canada, Belgium (unspecified route)
- 31 Dec 2021 Galapagos has patents pending for GLP 4586 in the Taiwan and other foreign countries
- 04 Dec 2020 GLP 4586 is available for licensing as of 30 Nov 2020. https://www.glpg.com/partnering (Galapagos website, November 2020)